Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
120M
-
Number of holders
-
132
-
Total 13F shares, excl. options
-
71.7M
-
Shares change
-
+68.9K
-
Total reported value, excl. options
-
$683M
-
Value change
-
-$6.79M
-
Put/Call ratio
-
0.94
-
Number of buys
-
88
-
Number of sells
-
-57
-
Price
-
$9.53
Significant Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q2 2023
175 filings reported holding ARQT - Arcutis Biotherapeutics, Inc. - Common Stock as of Q2 2023.
Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) has 132 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.7M shares
of 120M outstanding shares and own 59.66% of the company stock.
Largest 10 shareholders include FMR LLC (9.21M shares), Frazier Life Sciences Management, L.P. (8.68M shares), STATE STREET CORP (5.23M shares), Rubric Capital Management LP (4.88M shares), JENNISON ASSOCIATES LLC (4.29M shares), BlackRock Inc. (4.23M shares), Polar Capital Holdings Plc (3.13M shares), Bain Capital Life Sciences Investors, LLC (3M shares), VANGUARD GROUP INC (2.65M shares), and MARSHALL WACE, LLP (2.32M shares).
This table shows the top 132 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.